Donanemab is an investigational, intravenously administered amyloid beta-directed antibody proposed for the treatment of Alzheimer disease.
If you have a Hayes login, click here to view the full report on the Knowledge Center.
Donanemab is an investigational, intravenously administered amyloid beta-directed antibody proposed for the treatment of Alzheimer disease.
If you have a Hayes login, click here to view the full report on the Knowledge Center.